B. Bloquel, H. Jeulin, C. Burty, L. Letranchant, and C. , Occult hepatitis B infection in patients infected with HIV: Report of two cases of hepatitis B reactivation and prevalence in a hospital cohort, Journal of Medical Virology, vol.78, issue.2, pp.206-218
DOI : 10.1002/jmv.21685

A. Mammette and P. D. , Virologie médicale, 2002.

A. Alberti, N. Clumeck, S. Collins, W. Gerlich, J. Lundgren et al., SHORT STATEMENT OF THE FIRST EUROPEAN CONSENSUS CONFERENCE ON THE TREATMENT OF CHRONIC HEPATITIS B AND C IN HIV CO-INFECTED PATIENTS, Journal of Hepatology, vol.42, issue.5, pp.615-639, 2005.
DOI : 10.1016/j.jhep.2005.03.003

M. I. Allen, M. Deslauriers, C. W. Andrews, G. A. Tipples, K. A. Walters et al., Identification and characterization of mutations in hepatitis B virus resistant to lamivudine, Hepatology, vol.15, issue.6, pp.1670-1677, 1998.
DOI : 10.1002/hep.510270628

I. E. Andernach, J. M. Hubschen, and C. P. Muller, Hepatitis B virus: the genotype E puzzle, Reviews in Medical Virology, vol.37, issue.8-9, pp.231-271, 2009.
DOI : 10.1080/00034983.1954.11685622

N. M. Araujo, M. Branco-vieira, A. C. Silva, J. H. Pilotto, B. Grinsztejn et al., Occult hepatitis B virus infection in HIV-infected patients: Evaluation of biochemical, virological and molecular parameters, Hepatology Research, vol.73, issue.2, pp.1194-203, 2008.
DOI : 10.1016/0016-5085(90)91035-5

P. Arauz-ruiz, H. Norder, B. H. Robertson, and L. O. Magnius, Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America, Journal of General Virology, vol.41, issue.8, pp.2059-73, 2002.
DOI : 10.1172/JCI115500

A. Ascherio, S. M. Zhang, M. A. Hernan, M. J. Olek, P. M. Coplan et al., Hepatitis B Vaccination and the Risk of Multiple Sclerosis, New England Journal of Medicine, vol.344, issue.5, pp.327-359, 2001.
DOI : 10.1056/NEJM200102013440502

W. H. Bancroft, F. K. Mundon, and P. K. Russell, Detection of additional antigenic determinants of hepatitis B antigen, J Immunol, vol.109, issue.4, pp.842-850, 1972.

F. Bani-sadr, P. Palmer, C. Scieux, and J. M. Molina, Ninety???Six???Week Efficacy of Combination Therapy with Lamivudine and Tenofovir in Patients Coinfected with HIV???1 and Wild???Type Hepatitis B Virus, Clinical Infectious Diseases, vol.39, issue.7, pp.1062-1066, 2004.
DOI : 10.1097/00002030-200301030-00002

A. Bartholomeusz and S. Locarnini, Hepatitis B virus mutations associated with antiviral therapy, Journal of Medical Virology, vol.38, issue.S1, pp.52-57, 2006.
DOI : 10.1002/jmv.20608

J. Beck and M. Nassal, Hepatitis B virus replication, World Journal of Gastroenterology, vol.13, issue.1, pp.48-64, 2007.
DOI : 10.3748/wjg.v13.i1.48

Y. Benhamou, Hepatitis B in the HIV-Coinfected Patient, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.45, issue.Supplement 2, pp.57-65, 2007.
DOI : 10.1097/QAI.0b013e318068d1dd

Y. Benhamou, E. Dohin, F. Lunel-fabiani, T. Poynard, J. M. Huraux et al., Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients, The Lancet, vol.345, issue.8946, pp.396-403, 1995.
DOI : 10.1016/S0140-6736(95)90388-7

B. Bloquel, H. Jeulin, C. Burty, L. Letranchant, and C. , Occult hepatitis B infection in patients infected with HIV: Report of two cases of hepatitis B reactivation and prevalence in a hospital cohort, Journal of Medical Virology, vol.78, issue.2, pp.206-218
DOI : 10.1002/jmv.21685

N. J. Bodsworth, D. A. Cooper, and B. Donovan, The Influence of Human Immunodeficiency Virus Type 1 Infection on the Development of the Hepatitis B Virus Carrier State, Journal of Infectious Diseases, vol.163, issue.5, pp.1138-1178, 1991.
DOI : 10.1093/infdis/163.5.1138

K. Borroto-esoda, M. D. Miller, and S. Arterburn, Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials, Journal of Hepatology, vol.47, issue.4, pp.492-500, 2007.
DOI : 10.1016/j.jhep.2007.06.011

R. Bruno, P. Sacchi, A. Malfitano, and G. Filice, YMDD-mutant HBV strain as a cause of liver failure in an HIV-infected patient, Gastroenterology, vol.121, issue.4, pp.1027-1035, 2001.
DOI : 10.1053/gast.2001.28586

A. J. Chamorro, J. L. Casado, D. Bellido, and S. Moreno, Reactivation of hepatitis B in an HIV-infected patient with antibodies against hepatitis B core antigen as the only serological marker, European Journal of Clinical Microbiology & Infectious Diseases, vol.188, issue.7, pp.492-496, 2005.
DOI : 10.7326/0003-4819-101-6-795

T. T. Chang, R. G. Gish, R. De-man, A. Gadano, J. Sollano et al., A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B, New England Journal of Medicine, vol.354, issue.10, pp.1001-1011, 2006.
DOI : 10.1056/NEJMoa051285

B. F. Chen, J. H. Kao, C. J. Liu, D. S. Chen, and P. J. Chen, Genotypic dominance and novel recombinations in HBV genotype B and C co-infected intravenous drug users, Journal of Medical Virology, vol.61, issue.1, pp.13-22, 2004.
DOI : 10.1099/0022-1317-82-4-883

K. Chen, Y. Wei, A. Alter, G. C. Sharp, and H. Braley-mullen, Chemokine expression during development of fibrosis versus resolution in a murine model of granulomatous experimental autoimmune thyroiditis, Journal of Leukocyte Biology, vol.150, issue.3, pp.716-740, 2005.
DOI : 10.1530/eje.0.1500225

L. Chen, F. Liu, X. Fan, J. Gao, N. Chen et al., Detection of hepatitis B surface antigen, hepatitis B core antigen, and hepatitis B virus DNA in parotid tissues, International Journal of Infectious Diseases, vol.13, issue.1, pp.20-23, 2009.
DOI : 10.1016/j.ijid.2008.03.015

M. Ciotti, F. Marcuccilli, T. Guenci, M. G. Prignano, and C. F. Perno, Evaluation of the Abbott RealTime HBV DNA Assay and Comparison to the Cobas AmpliPrep/Cobas TaqMan 48 Assay in Monitoring Patients with Chronic Cases of Hepatitis B, Journal of Clinical Microbiology, vol.46, issue.4, pp.1517-1526, 2008.
DOI : 10.1128/JCM.02046-07

S. J. Clark, S. Creighton, M. Horner, H. M. Smith, C. Portmann et al., Reactivation of latent hepatitis B virus infection with HIV-related immunosuppression, International Journal of STD & AIDS, vol.17, issue.1, pp.67-76, 2006.
DOI : 10.1258/095646206775220612

C. Stuart, J. W. , M. Velema, R. Schuurman, C. A. Boucher et al., Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy, Journal of Medical Virology, vol.18, issue.3, pp.441-446, 2009.
DOI : 10.1002/jmv.21422

R. Colonno, R. Rose, and K. Pokornowski, Four years assessment of entecavir resistance in nucleoside-naive and lamivudine refractory patients, J Hepatol, vol.1, p.294, 2007.

C. Confavreux, S. Suissa, P. Saddier, V. Bourdes, and S. Vukusic, Vaccinations and the Risk of Relapse in Multiple Sclerosis, New England Journal of Medicine, vol.344, issue.5, pp.319-345, 2001.
DOI : 10.1056/NEJM200102013440501

D. Silva, L. C. , J. R. Pinho, R. Sitnik, L. E. Da-fonseca et al., Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B, Journal of Gastroenterology, vol.36, issue.7, pp.476-85, 2001.
DOI : 10.1007/s005350170071

S. Datta, A. Banerjee, P. K. Chandra, A. Chowdhury, and R. Chakravarty, Genotype, phylogenetic analysis, and transmission pattern of occult hepatitis B virus (HBV) infection in families of asymptomatic HBsAg carriers, Journal of Medical Virology, vol.36, issue.1, pp.53-62, 2006.
DOI : 10.1099/0022-1317-81-5-1165

W. E. Delaney, H. Yang, C. E. Westland, K. Das, E. Arnold et al., The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro, Journal of Virology, vol.77, issue.21, pp.11833-11874, 2003.
DOI : 10.1128/JVI.77.21.11833-11841.2003

J. L. Dienstag, J. Cianciara, S. Karayalcin, K. V. Kowdley, B. Willems et al., Durability of serologic response after lamivudine treatment of chronic hepatitis B, Hepatology, vol.9, issue.4, pp.748-55, 2003.
DOI : 10.1046/j.1365-2893.2002.00357.x

V. Escuret, A. Martin, D. Durantel, R. Parent, O. Hantz et al., Novel Alpha Interferon (IFN-??) Variant with Improved Inhibitory Activity against Hepatitis C Virus Genotype 1 Replication Compared to IFN-??2b Therapy in a Subgenomic Replicon System, Antimicrobial Agents and Chemotherapy, vol.50, issue.12, pp.3984-91, 2006.
DOI : 10.1128/AAC.00199-06

URL : https://hal.archives-ouvertes.fr/inserm-00134586

P. Filippini, N. Coppola, R. Pisapia, C. Scolastico, C. Marrocco et al., Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy, AIDS, vol.20, issue.9, pp.1253-60, 2006.
DOI : 10.1097/01.aids.0000232232.41877.2a

E. Flodgren, S. Bengtsson, M. Knutsson, E. A. Strebkova, A. H. Kidd et al., Recent high incidence of fulminant hepatitis in Samara, Russia: molecular analysis of prevailing hepatitis B and D virus strains, J Clin Microbiol, vol.38, issue.9, pp.3311-3317, 2000.

J. E. Gallant, S. Staszewski, A. L. Pozniak, E. Dejesus, J. M. Suleiman et al., Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients<SUBTITLE>A 3-Year Randomized Trial</SUBTITLE>, JAMA, vol.292, issue.2, pp.191-201, 2004.
DOI : 10.1001/jama.292.2.191

D. Ganem and A. M. Prince, Hepatitis B Virus Infection ??? Natural History and Clinical Consequences, New England Journal of Medicine, vol.350, issue.11, pp.1118-1147, 2004.
DOI : 10.1056/NEJMra031087

B. C. Gartner, W. Jung, C. Welsch, J. Fischinger, J. Schubert et al., Permanent loss of anti-HBc after reactivation of hepatitis B virus infection in an anti-HBs and anti-HBc-positive patient after allogeneic stem cell transplantation, Journal of Clinical Virology, vol.38, issue.2, pp.146-154, 2007.
DOI : 10.1016/j.jcv.2006.03.014

R. Girones and R. H. Miller, Mutation rate of the hepadnavirus genome, Virology, vol.170, issue.2, pp.595-602, 1989.
DOI : 10.1016/0042-6822(89)90455-8

R. G. Gish, H. Trinh, N. Leung, F. K. Chan, M. W. Fried et al., Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: A two-year study, Journal of Hepatology, vol.43, issue.1, pp.60-66, 2005.
DOI : 10.1016/j.jhep.2005.02.017

D. Glebe, Recent advances in hepatitis B virus research: A German point of view, World Journal of Gastroenterology, vol.13, issue.1, pp.8-13, 2007.
DOI : 10.3748/wjg.v13.i1.8

P. Gripon, I. Cannie, and S. Urban, Efficient Inhibition of Hepatitis B Virus Infection by Acylated Peptides Derived from the Large Viral Surface Protein, Journal of Virology, vol.79, issue.3, pp.1613-1635, 2005.
DOI : 10.1128/JVI.79.3.1613-1622.2005

S. Gunther, Genetic variation in HBV infection: genotypes and mutants, Journal of Clinical Virology, vol.36, issue.1, pp.3-11, 2006.
DOI : 10.1016/S1386-6532(06)80002-8

S. J. Hadziyannis, N. C. Tassopoulos, E. J. Heathcote, T. T. Chang, G. Kitis et al., Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen???Negative Chronic Hepatitis B, New England Journal of Medicine, vol.348, issue.9, pp.800-807, 2003.
DOI : 10.1056/NEJMoa021812

K. Hino, A. A. Basuni, J. Ireland, A. Newell, J. Mphahlele et al., Reappearance of hepatitis B surface antigen in immunocompromised individuals: reinfection or reactivation?, Digestive Diseases and Sciences, vol.47, issue.2, pp.415-423, 2002.
DOI : 10.1023/A:1013794711235

M. Hofer, H. I. Joller-jemelka, P. J. Grob, R. Luthy, and M. Opravil, Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only, European Journal of Clinical Microbiology & Infectious Diseases, vol.172, issue.1, pp.6-13, 1998.
DOI : 10.1007/BF01584356

J. Huraux, J. Nicolas, H. Agut, and H. Peigue-lafeuille, Traité de virologie médicale INVS Calendrier vaccinal, 2003.

H. L. Janssen, M. Van-zonneveld, H. Senturk, S. Zeuzem, U. S. Akarca et al., Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial, The Lancet, vol.365, issue.9454, pp.123-132, 2005.
DOI : 10.1016/S0140-6736(05)17701-0

D. Jeantet, I. Chemin, B. Mandrand, A. Tran, F. Zoulim et al., Cloning and expression of surface antigens from occult chronic hepatitis B virus infections and their recognition by commercial detection assays, Journal of Medical Virology, vol.60, issue.4, pp.508-523, 2004.
DOI : 10.1099/0022-1317-81-5-1165

J. H. Kao, P. J. Chen, M. Y. Lai, and D. S. Chen, Occult Hepatitis B Virus Infection and Clinical Outcomes of Patients with Chronic Hepatitis C, Journal of Clinical Microbiology, vol.40, issue.11, pp.4068-71, 2002.
DOI : 10.1128/JCM.40.11.4068-4071.2002

M. G. Katze, Y. He, M. Gale, and J. , Viruses and interferon: a fight for supremacy, Nature Reviews Immunology, vol.6, issue.9, pp.675-87, 2002.
DOI : 10.1038/11737

S. Kobayashi, T. Ide, and M. Sata, Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers, Journal of Hepatology, vol.34, issue.4, pp.584-590, 2001.
DOI : 10.1016/S0168-8278(00)00023-4

T. Koibuchi, A. Hitani, T. Nakamura, N. Nojiri, K. Nakajima et al., Predominance of genotype A HBV in an HBV-HIV-1 dually positive population compared with an HIV-1-negative counterpart in Japan, Journal of Medical Virology, vol.58, issue.4, pp.435-475, 2001.
DOI : 10.1002/(SICI)1096-9071(199906)58:2<105::AID-JMV1>3.0.CO;2-3

K. Koike, Hepatitis B Virus HBx Gene and Hepatocarcinogenesis, Intervirology, vol.38, issue.3-4, pp.3-4, 1995.
DOI : 10.1159/000150424

J. Korenman, B. Baker, J. Waggoner, J. E. Everhart, A. M. Di-bisceglie et al., Long-Term Remission of Chronic Hepatitis B after Alpha-Interferon Therapy, Annals of Internal Medicine, vol.114, issue.8, pp.629-663, 1991.
DOI : 10.7326/0003-4819-114-8-629

K. Lacombe, J. Gozlan, P. Y. Boelle, L. Serfaty, F. Zoulim et al., Long-term hepatitis B virus dynamics in HIV???hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate, AIDS, vol.19, issue.9, pp.907-922, 2005.
DOI : 10.1097/01.aids.0000171404.07995.5c

K. Lacombe, V. Massari, P. M. Girard, L. Serfaty, J. Gozlan et al., Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV, AIDS, vol.20, issue.3, pp.419-446, 2006.
DOI : 10.1097/01.aids.0000200537.86984.0e

C. L. Lai, C. K. Ching, A. K. Tung, E. Li, J. Young et al., Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: A placebo-controlled trial, Hepatology, vol.25, issue.1, pp.241-245, 1997.
DOI : 10.1002/hep.510250144

C. L. Lai, E. Gane, Y. F. Liaw, C. W. Hsu, S. Thongsawat et al., Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B, New England Journal of Medicine, vol.357, issue.25, pp.2576-88, 2007.
DOI : 10.1056/NEJMoa066422

C. L. Lai, D. Shouval, A. S. Lok, T. T. Chang, H. Cheinquer et al., Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B, New England Journal of Medicine, vol.354, issue.10, pp.1011-1031, 2006.
DOI : 10.1056/NEJMoa051287

D. R. Langley, A. W. Walsh, C. J. Baldick, B. J. Eggers, R. E. Rose et al., Inhibition of Hepatitis B Virus Polymerase by Entecavir, Journal of Virology, vol.81, issue.8, pp.3992-4001, 2007.
DOI : 10.1128/JVI.02395-06

L. Bouvier and G. L. , The Heterogeneity of Australia Antigen, Journal of Infectious Diseases, vol.123, issue.6, pp.671-676, 1971.
DOI : 10.1093/infdis/123.6.671

J. S. Lee, E. T. Park, S. S. Kang, E. S. Gu, J. S. Kim et al., Clevudine Demonstrates Potent Antiviral Activity in Na??ve Chronic Hepatitis B Patients, Intervirology, vol.53, issue.2, pp.83-89, 2009.
DOI : 10.1159/000264197

Y. F. Liaw, R. N. Chien, and C. T. Yeh, No benefit to continue lamivudine therapy after emergence of YMDD mutations, Antivir Ther, vol.9, issue.2, pp.257-62, 2004.

Y. F. Liaw and C. M. Chu, Hepatitis B virus infection, The Lancet, vol.373, issue.9663, pp.582-92, 2009.
DOI : 10.1016/S0140-6736(09)60207-5

Y. F. Liaw, E. Gane, N. Leung, S. Zeuzem, Y. Wang et al., 2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B, Gastroenterology, vol.136, issue.2, pp.486-95, 2009.
DOI : 10.1053/j.gastro.2008.10.026

Y. F. Liaw, J. J. Sung, W. C. Chow, G. Farrell, C. Z. Lee et al., Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease, New England Journal of Medicine, vol.351, issue.15, pp.1521-1552, 2004.
DOI : 10.1056/NEJMoa033364

V. Lo-re, I. Frank, R. Gross, J. Dockter, J. M. Linnen et al., Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients, J Acquir Immune Defic Syndr, vol.44, issue.3, pp.315-335, 2007.

S. Locarnini, Molecular Virology of Hepatitis B Virus, Seminars in Liver Disease, vol.24, issue.1, pp.3-10, 2004.
DOI : 10.1055/s-2004-828672

S. Locarnini, A. Hatzakis, J. Heathcote, E. B. Keeffe, T. J. Liang et al., Management of antiviral resistance in patients with chronic hepatitis B, Antivir Ther, vol.9, issue.5, pp.679-93, 2004.

A. S. Lok, C. L. Lai, N. Leung, G. B. Yao, Z. Y. Cui et al., Long-term safety of lamivudine treatment in patients with chronic hepatitis B, Gastroenterology, vol.125, issue.6, pp.1714-1736, 2003.
DOI : 10.1053/j.gastro.2003.09.033

A. Lukhwareni, R. J. Burnett, S. G. Selabe, M. O. Mzileni, and M. J. Mphahlele, Increased detection of HBV DNA in HBsAg-positive and HBsAg-negative South African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a Tertiary Hospital, Journal of Medical Virology, vol.30, issue.3, pp.406-418, 2009.
DOI : 10.1093/infdis/169.3.628

L. O. Magnius and H. Norder, Subtypes, Genotypes and Molecular Epidemiology of the Hepatitis B Virus as Reflected by Sequence Variability of the S-Gene, Intervirology, vol.38, issue.1-2, pp.24-34, 1995.
DOI : 10.1159/000150411

A. Mammette and P. Dény, Virologie médicale, 2002.

C. Manegold, C. Hannoun, A. Wywiol, M. Dietrich, S. Polywka et al., Reactivation of Hepatitis B Virus Replication Accompanied by Acute Hepatitis in Patients Receiving Highly Active Antiretroviral Therapy, Clinical Infectious Diseases, vol.349, issue.9063, pp.144-152, 2001.
DOI : 10.1016/S0140-6736(96)11431-8

P. Marcellin, E. J. Heathcote, M. Buti, E. Gane, R. A. De-man et al., Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B, New England Journal of Medicine, vol.359, issue.23, pp.2442-55, 2008.
DOI : 10.1056/NEJMoa0802878

P. Maupas, A. Goudeau, P. Coursaget, J. Drucker, and P. Bagros, IMMUNISATION AGAINST HEPATITIS B IN MAN, The Lancet, vol.307, issue.7974, pp.1367-70, 1976.
DOI : 10.1016/S0140-6736(76)93023-3

C. Mayerat, A. Mantegani, and P. C. Frei, Does hepatitis B virus (HBV) genotype influence the clinical outcome of HBV infection?, Journal of Viral Hepatitis, vol.6, issue.4, pp.299-304, 1999.
DOI : 10.1136/gut.19.11.1022

R. Moucari, V. Mackiewicz, O. Lada, M. P. Ripault, C. Castelnau et al., Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients, Hepatology, vol.37, issue.Suppl 2, pp.1151-1158, 2009.
DOI : 10.1053/jhep.2003.50148

M. N. Mulders, V. Venard, M. Njayou, A. P. Edorh, A. O. Bola-oyefolu et al., Low Genetic Diversity despite Hyperendemicity of Hepatitis B Virus Genotype E throughout West Africa, The Journal of Infectious Diseases, vol.190, issue.2, pp.400-408, 2004.
DOI : 10.1086/421502

D. Neau, M. Winnock, A. C. Jouvencel, M. Faure, L. Castera et al., Occult hepatitis B virus infection in HIV-infected patients with isolated antibodies to hepatitis B core antigen: Aquitaine cohort, Clin Infect Dis, vol.40, issue.5, pp.2002-2003, 2005.

G. Nebbia, A. Garcia-diaz, U. Ayliffe, C. Smith, M. Dervisevic et al., Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons, Journal of Medical Virology, vol.64, issue.10, pp.1464-71, 2007.
DOI : 10.1002/jmv.20954

M. Nelson, S. Portsmouth, J. Stebbing, M. Atkins, A. Barr et al., An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals, AIDS, vol.17, issue.1, pp.7-10, 2003.
DOI : 10.1097/00002030-200301030-00002

C. Niederau, T. Heintges, S. Lange, G. Goldmann, C. M. Niederau et al., Long-Term Follow-up of HBeAg-Positive Patients Treated with Interferon Alfa for Chronic Hepatitis B, New England Journal of Medicine, vol.334, issue.22, pp.1422-1429, 1996.
DOI : 10.1056/NEJM199605303342202

M. Nunez, P. Rios, M. Perez-olmeda, and V. Soriano, Lack of ???occult??? hepatitis B virus infection in HIV-infected patients, AIDS, vol.16, issue.15, pp.2099-101, 2002.
DOI : 10.1097/00002030-200210180-00024

H. Okamoto, M. Imai, F. Tsuda, T. Tanaka, Y. Miyakawa et al., Point mutation in the S gene of hepatitis B virus for a d/y or w/r subtypic change in two blood donors carrying a surface antigen of compound subtype adyr or adwr, J Virol, issue.10, pp.61-3030, 1987.

C. M. Olinger, N. V. Lazouskaya, V. F. Eremin, and C. P. Muller, Multiple genotypes and subtypes of hepatitis B and C viruses in Belarus: similarities with Russia and western European influences, Clinical Microbiology and Infection, vol.14, issue.6, 2008.
DOI : 10.1111/j.1469-0691.2008.01988.x

C. M. Olinger, V. Venard, M. Njayou, A. O. Oyefolu, I. Maiga et al., Phylogenetic analysis of the precore/core gene of hepatitis B virus genotypes E and A in West Africa: new subtypes, mixed infections and recombinations, Journal of General Virology, vol.87, issue.5, pp.1163-73, 2006.
DOI : 10.1099/vir.0.81614-0

R. Pastor, F. Habersetzer, S. Fafi-kremer, M. Doffoel, T. F. Baumert et al., Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naive patients, World Journal of Gastroenterology, vol.15, issue.6, pp.753-758, 2009.
DOI : 10.3748/wjg.15.753

R. P. Perrillo, Factors influencing response to interferon in chronic hepatitis B: Implications for Asian and western populations, Hepatology, vol.85, issue.6, pp.1433-1438, 1990.
DOI : 10.1093/infdis/143.6.772

M. G. Peters, Diagnosis and management of hepatitis B virus and HIV coinfection, Top HIV Med, vol.15, issue.5, pp.163-169, 2007.

M. G. Peters, H. Hann-hw, P. Martin, E. J. Heathcote, P. Buggisch et al., Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary???s Hospital, London, England); C. Trepo (Hopital H??tel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ)., Gastroenterology, vol.126, issue.1, pp.91-101, 2004.
DOI : 10.1053/j.gastro.2003.10.051

J. Petersen, M. Dandri, W. Mier, M. Lutgehetmann, T. Volz et al., Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein, Nature Biotechnology, vol.46, issue.3, pp.335-376, 2008.
DOI : 10.1093/oxfordjournals.molbev.a026417

L. Piroth, C. Binquet, M. Vergne, A. Minello, C. Livry et al., The evolution of hepatitis B virus serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV infected patients, Journal of Hepatology, vol.36, issue.5, pp.681-687, 2002.
DOI : 10.1016/S0168-8278(02)00019-3

L. Piroth, M. E. Lafon, C. Binquet, P. Bertillon, A. Gervais et al., Occult hepatitis B in HIV-HCV coinfected patients, Scandinavian Journal of Infectious Diseases, vol.40, issue.10, pp.835-844, 2008.
DOI : 10.1080/00365540801918511

T. Pollicino, G. Raffa, L. Costantino, A. Lisa, C. Campello et al., Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma, Hepatology, vol.78, issue.2, pp.277-85, 2007.
DOI : 10.1053/gast.2001.28586

P. Pontisso, L. Vidalino, S. Quarta, and A. Gatta, Biological and clinical implications of HBV infection in peripheral blood mononuclear cells, Autoimmunity Reviews, vol.8, issue.1, pp.13-20, 2008.
DOI : 10.1016/j.autrev.2008.07.016

G. Raimondo, T. Pollicino, I. Cacciola, and G. Squadrito, Occult hepatitis B virus infection, Journal of Hepatology, vol.46, issue.1, pp.160-70, 2007.
DOI : 10.1016/j.jhep.2006.10.007

J. M. Sanchez-tapias, J. Costa, A. Mas, M. Bruguera, and J. Rodes, Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients, Gastroenterology, vol.123, issue.6, pp.1848-56, 2002.
DOI : 10.1053/gast.2002.37041

E. A. Santos, C. F. Yoshida, V. C. Rolla, J. M. Mendes, I. F. Vieira et al., Frequent occult hepatitis B virus infection in patients infected with human immunodeficiency virus type 1, Eur J Clin Microbiol Infect Dis, vol.22, issue.2, pp.92-100, 2003.

J. I. Seok, D. K. Lee, C. H. Lee, M. S. Park, S. Y. Kim et al., Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA, Hepatology, vol.67, issue.6, pp.2080-2086, 2009.
DOI : 10.1212/01.wnl.0000240078.47020.5e

J. Sheldon, N. Camino, B. Rodes, A. Bartholomeusz, M. Kuiper et al., Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir, Antivir Ther, vol.10, issue.6, pp.727-761, 2005.

J. Sheldon, B. Rodes, F. Zoulim, A. Bartholomeusz, and V. Soriano, Mutations affecting the replication capacity of the hepatitis B virus, Journal of Viral Hepatitis, vol.70, issue.7, pp.427-461, 2006.
DOI : 10.1053/jhep.2003.50012

V. Soriano, J. Sheldon, P. Garcia-gasco, and E. Vispo, Lack of anti-HIV activity of entecavir in an HIV patient coinfected with hepatitis B and delta viruses, AIDS, vol.21, issue.16, pp.2253-2257, 2007.
DOI : 10.1097/QAD.0b013e3282f08bae

C. Stephan, A. Berger, A. Carlebach, T. Lutz, M. Bickel et al., Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus, Journal of Antimicrobial Chemotherapy, vol.56, issue.6, pp.1087-93, 2005.
DOI : 10.1086/424012

L. Stuyver, S. De-gendt, C. Van-geyt, F. Zoulim, M. Fried et al., A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness, Journal of General Virology, vol.65, issue.1, pp.67-74, 2000.
DOI : 10.1016/0166-0934(91)90004-J

W. Szmuness, Large-scale efficacy trials of hepatitis B vaccines in the USA: Baseline data and protocols, Journal of Medical Virology, vol.227, issue.4, pp.327-367, 1979.
DOI : 10.7326/0003-4819-83-4-489

R. B. Takkenberg, C. J. Weegink, H. L. Zaaijer, and H. W. Reesink, New developments in antiviral therapy for chronic hepatitis B, Vox Sanguinis, vol.48, issue.3, 2009.
DOI : 10.1111/j.1478-3231.2008.01696.x

D. J. Tenney, R. E. Rose, C. J. Baldick, S. M. Levine, K. A. Pokornowski et al., Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present, Antimicrobial Agents and Chemotherapy, vol.51, issue.3, pp.902-913, 2007.
DOI : 10.1128/AAC.00833-06

D. J. Tenney, R. E. Rose, C. J. Baldick, K. A. Pokornowski, B. J. Eggers et al., Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-na??ve patients is rare through 5 years of therapy, Hepatology, vol.51, issue.4 Suppl. 1, pp.1503-1517, 2009.
DOI : 10.1128/AAC.01440-06

V. Thibault, Y. Benhamou, C. Seguret, M. Bochet, C. Katlama et al., Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus, J Clin Microbiol, vol.37, issue.9, pp.3013-3019, 1999.

C. L. Thio, Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment, Semin Liver Dis, vol.23, issue.2, pp.125-161, 2003.

F. Tine, A. Liberati, A. Craxi, P. Almasio, and L. Pagliaro, Interferon treatment in patients with chronic hepatitis B: A meta-analysis of the published literature, Journal of Hepatology, vol.18, issue.2, pp.154-62, 1993.
DOI : 10.1016/S0168-8278(05)80241-7

M. Torbenson and D. L. Thomas, Occult hepatitis B, The Lancet Infectious Diseases, vol.2, issue.8, pp.479-86, 2002.
DOI : 10.1016/S1473-3099(02)00345-6

J. Torresi, L. Earnest-silveira, G. Deliyannis, K. Edgtton, H. Zhuang et al., Reduced Antigenicity of the Hepatitis B Virus HBsAg Protein Arising as a Consequence of Sequence Changes in the Overlapping Polymerase Gene That Are Selected by Lamivudine Therapy, Virology, vol.293, issue.2, pp.305-318, 2002.
DOI : 10.1006/viro.2001.1246

F. Van-bommel, T. Wunsche, S. Mauss, P. Reinke, A. Bergk et al., Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection, Hepatology, vol.125, issue.6, pp.1421-1426, 2004.
DOI : 10.1016/S0016-5085(03)00939-9

T. G. Vassiliadis, O. Giouleme, G. Koumerkeridis, H. Koumaras, K. Tziomalos et al., chronic hepatitis B patients: A 4-year study, Journal of Gastroenterology and Hepatology, vol.46, issue.1, 2009.
DOI : 10.3748/wjg.v12.i15.2417

S. Villet, C. Pichoud, G. Billioud, L. Barraud, S. Durantel et al., Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure, Journal of Hepatology, vol.48, issue.5, pp.747-55, 2008.
DOI : 10.1016/j.jhep.2008.01.027

A. Wasley, J. T. Miller, and L. Finelli, Surveillance for acute viral hepatitis--United States, MMWR Surveill Summ, vol.56, issue.3, pp.1-24, 2005.

D. K. Wong, A. M. Cheung, K. O-'rourke, C. D. Naylor, A. S. Detsky et al., Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B, Annals of Internal Medicine, vol.119, issue.4, pp.312-335, 1993.
DOI : 10.7326/0003-4819-119-4-199308150-00011

T. L. Wright, Clinical Trial Results and Treatment Resistance with Lamivudine in Hepatitis B, Seminars in Liver Disease, vol.24, issue.1, pp.31-37, 2004.
DOI : 10.1055/s-2004-828676

G. Y. Wu and H. S. Chen, Novel approaches towards conquering hepatitis B virus infection, World Journal of Gastroenterology, vol.13, issue.6, pp.830-836, 2007.
DOI : 10.3748/wjg.v13.i6.830

URL : http://europepmc.org/articles/pmc4065916?pdf=render

K. Wursthorn, M. Lutgehetmann, M. Dandri, T. Volz, P. Buggisch et al., Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B, Hepatology, vol.46, issue.3, pp.675-84, 2006.
DOI : 10.1002/hep.21282

X. Xiong, C. Flores, H. Yang, J. J. Toole, and C. S. Gibbs, Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovirin vitro, Hepatology, vol.34, issue.4, pp.1669-73, 1998.
DOI : 10.1002/hep.510280629

M. F. Yuen, T. Kato, M. Mizokami, A. O. Chan, J. C. Yuen et al., Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations, Journal of Hepatology, vol.39, issue.5, pp.850-855, 2003.
DOI : 10.1016/S0168-8278(03)00388-X

F. Zoulim, Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic Hepatitis B virus infection, Antiviral Research, vol.64, issue.1, pp.1-15, 2004.
DOI : 10.1016/S0166-3542(04)00162-7

URL : https://hal.archives-ouvertes.fr/inserm-00136413

F. Zoulim, In Vitro Models for Studying Hepatitis B Virus Drug Resistance, Seminars in Liver Disease, vol.26, issue.2, pp.171-80, 2006.
DOI : 10.1055/s-2006-939759

F. Zoulim, Emerging drugs for hepatitis B, Expert Opinion on Emerging Drugs, vol.10, issue.2, pp.199-217, 2007.
DOI : 10.1016/j.jhep.2004.11.035

URL : https://hal.archives-ouvertes.fr/inserm-00162225

F. Zoulim and S. Locarnini, Hepatitis B Virus Resistance to Nucleos(t)ide Analogues, Gastroenterology, vol.137, issue.5, pp.1593-608, 2009.
DOI : 10.1053/j.gastro.2009.08.063

F. Zoulim, T. Poynard, F. Degos, A. Slama, A. Hasnaoui et al., A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine, Journal of Viral Hepatitis, vol.9, issue.4, pp.278-88, 2006.
DOI : 10.1111/j.1572-0241.2005.41957.x

URL : https://hal.archives-ouvertes.fr/inserm-00135954

A. Alberti, N. Clumeck, S. Collins, W. Gerlich, J. Lundgren et al., SHORT STATEMENT OF THE FIRST EUROPEAN CONSENSUS CONFERENCE ON THE TREATMENT OF CHRONIC HEPATITIS B AND C IN HIV CO-INFECTED PATIENTS, Journal of Hepatology, vol.42, issue.5, pp.615-624, 2005.
DOI : 10.1016/j.jhep.2005.03.003

F. Bani-sadr, P. Palmer, C. Scieux, and J. Molina, Ninety???Six???Week Efficacy of Combination Therapy with Lamivudine and Tenofovir in Patients Coinfected with HIV???1 and Wild???Type Hepatitis B Virus, Clinical Infectious Diseases, vol.39, issue.7, pp.1062-1064, 2004.
DOI : 10.1097/00002030-200301030-00002

Y. Benhamou, Hepatitis B in the HIV-Coinfected Patient, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.45, issue.Supplement 2, pp.57-65, 2007.
DOI : 10.1097/QAI.0b013e318068d1dd

A. Chamorro, J. Casado, D. Bellido, and S. Moreno, Reactivation of hepatitis B in an HIV-infected patient with antibodies against hepatitis B core antigen as the only serological marker, European Journal of Clinical Microbiology & Infectious Diseases, vol.188, issue.7, pp.492-494, 2005.
DOI : 10.7326/0003-4819-101-6-795

I. Chemin and C. Trepo, Clinical impact of occult HBV infections, Journal of Clinical Virology, vol.34, pp.15-21, 2005.
DOI : 10.1016/S1386-6532(05)80005-8

S. Clark, S. Creighton, M. Horner, H. Smith, B. Portmann et al., Reactivation of latent hepatitis B virus infection with HIV-related immunosuppression, International Journal of STD & AIDS, vol.17, issue.1, pp.67-69, 2006.
DOI : 10.1258/095646206775220612

C. Stuart, J. Velema, M. Schuurman, R. Boucher, C. Hoepelman et al., Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy, Journal of Medical Virology, vol.18, issue.3, pp.441-445, 2009.
DOI : 10.1002/jmv.21422

S. Datta, A. Banerjee, P. Chandra, A. Chowdhury, and R. Chakravarty, Genotype, phylogenetic analysis, and transmission pattern of occult hepatitis B virus (HBV) infection in families of asymptomatic HBsAg carriers, Journal of Medical Virology, vol.36, issue.1, pp.53-59, 2006.
DOI : 10.1099/0022-1317-81-5-1165

G. Dore, D. Cooper, C. Barrett, L. Goh, B. Thakrar et al., Dual Efficacy of Lamivudine Treatment in Human Immunodeficiency Virus/Hepatitis B Virus???Coinfected Persons in a Randomized, Controlled Study (CAESAR), The Journal of Infectious Diseases, vol.180, issue.3, pp.607-613, 1999.
DOI : 10.1086/314942

P. Filippini, N. Coppola, R. Pisapia, C. Scolastico, C. Marrocco et al., Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy, AIDS, vol.20, issue.9, pp.1253-1260, 2006.
DOI : 10.1097/01.aids.0000232232.41877.2a

B. Gartner, W. Jung, C. Welsch, J. Fischinger, J. Schubert et al., Permanent loss of anti-HBc after reactivation of hepatitis B virus infection in an anti-HBs and anti-HBc-positive patient after allogeneic stem cell transplantation, Journal of Clinical Virology, vol.38, issue.2, pp.146-148, 2007.
DOI : 10.1016/j.jcv.2006.03.014

S. Gutierrez, S. Guillemi, N. Jahnke, V. Montessori, P. Harrigan et al., Tenofovir-Based Rescue Therapy for Advanced Liver Disease in 6 Patients Coinfected with HIV and Hepatitis B Virus and Receiving Lamivudine, Clinical Infectious Diseases, vol.12, issue.1, pp.28-30, 2008.
DOI : 10.1002/hep.21055

K. Hino, A. Basuni, J. Ireland, A. Newell, J. Mphahlele et al., Reappearance of hepatitis B surface antigen in immunocompromised individuals: Reinfection or reactivation?, Digestive Diseases and Sciences, vol.47, issue.2, pp.415-418, 2002.
DOI : 10.1023/A:1013794711235

M. Hofer, H. Joller-jemelka, P. Grob, R. Luthy, and M. Opravil, Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only, European Journal of Clinical Microbiology & Infectious Diseases, vol.172, issue.1, pp.6-13, 1998.
DOI : 10.1007/BF01584356

J. Kao, P. Chen, M. Lai, and D. Chen, Occult Hepatitis B Virus Infection and Clinical Outcomes of Patients with Chronic Hepatitis C, Journal of Clinical Microbiology, vol.40, issue.11, pp.4068-4071, 2002.
DOI : 10.1128/JCM.40.11.4068-4071.2002

V. Lo-re, . Iii, I. Frank, R. Gross, J. Dockter et al., Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients, J Acquir Immune Defic Syndr, vol.44, pp.315-320, 2007.

A. Lukhwareni, R. Burnett, S. Selabe, M. Mzileni, and M. Mphahlele, Increased detection of HBV DNA in HBsAg-positive and HBsAg-negative South African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a Tertiary Hospital, Journal of Medical Virology, vol.30, issue.3, pp.406-412, 2009.
DOI : 10.1093/infdis/169.3.628

C. Manegold, C. Hannoun, A. Wywiol, M. Dietrich, S. Polywka et al., Reactivation of Hepatitis B Virus Replication Accompanied by Acute Hepatitis in Patients Receiving Highly Active Antiretroviral Therapy, Clinical Infectious Diseases, vol.349, issue.9063, pp.144-148, 2001.
DOI : 10.1016/S0140-6736(96)11431-8

P. Miailhes, M. Trabaud, P. Pradat, B. Lebouche, M. Chevallier et al., Impact of Highly Active Antiretroviral Therapy (HAART) on the Natural History of Hepatitis B Virus (HBV) and HIV Coinfection: Relationship between Prolonged Efficacy of HAART and HBV Surface and Early Antigen Seroconversion, Clinical Infectious Diseases, vol.5, issue.6, pp.624-632, 2007.
DOI : 10.1016/S1473-3099(05)70141-9

D. Neau, M. Winnock, A. Jouvencel, M. Faure, L. Castera et al., Occult Hepatitis B Virus Infection in HIV-Infected Patients with Isolated Antibodies to Hepatitis B Core Antigen: Aquitaine Cohort, 2002-2003, Clinical Infectious Diseases, vol.30, issue.5, pp.750-753, 2002.
DOI : 10.1002/hep.510300525

G. Nebbia, A. Garcia-diaz, U. Ayliffe, C. Smith, S. Dervisevic et al., Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons, Journal of Medical Virology, vol.64, issue.10, pp.1464-1471, 2007.
DOI : 10.1002/jmv.20954

M. Nunez, P. Rios, M. Perez-olmeda, and V. Soriano, Lack of ???occult??? hepatitis B virus infection in HIV-infected patients, AIDS, vol.16, issue.15, pp.2099-2101, 2002.
DOI : 10.1097/00002030-200210180-00024

C. Olinger, P. Jutavijittum, J. Hubschen, A. Yousukh, B. Samountry et al., Possible New Hepatitis B Virus Genotype, Southeast Asia, Emerging Infectious Diseases, vol.14, issue.11, pp.1777-1780, 2008.
DOI : 10.3201/eid1411.080437

URL : https://wwwnc.cdc.gov/eid/article/14/11/pdfs/08-0437.pdf

C. Olinger, V. Venard, M. Njayou, A. Oyefolu, I. Maiga et al., Phylogenetic analysis of the precore/core gene of hepatitis B virus genotypes E and A in West Africa: new subtypes, mixed infections and recombinations, Journal of General Virology, vol.87, issue.5, pp.1163-1173, 2006.
DOI : 10.1099/vir.0.81614-0

M. Peters, Diagnosis and management of hepatitis B virus and HIV coinfection, Top HIV Med, vol.15, pp.163-166, 2007.

L. Piroth, C. Binquet, M. Vergne, A. Minello, C. Livry et al., The evolution of hepatitis B virus serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV infected patients, Journal of Hepatology, vol.36, issue.5, pp.681-686, 2002.
DOI : 10.1016/S0168-8278(02)00019-3

L. Piroth, F. Carrat, S. Larrat, I. Goderel, M. B. Payan et al., Prevalence and impact of GBV-C, SEN-V and HBV occult infections in HIV???HCV co-infected patients on HCV therapy, Journal of Hepatology, vol.49, issue.6, pp.892-898, 2008.
DOI : 10.1016/j.jhep.2008.06.024

M. Puoti, C. Torti, R. Bruno, G. Filice, and G. Carosi, Natural history of chronic hepatitis B in co-infected patients, Journal of Hepatology, vol.44, pp.65-70, 2006.
DOI : 10.1016/j.jhep.2005.11.015

G. Raffa, S. Maimone, A. Cargnel, T. Santantonio, G. Antonucci et al., Analysis of occult hepatitis B virus infection in liver tissue of HIV patients with chronic hepatitis C, AIDS, vol.21, issue.16, pp.2171-2175, 2007.
DOI : 10.1097/QAD.0b013e3282eea504

G. Raimondo, T. Pollicino, I. Cacciola, and G. Squadrito, Occult hepatitis B virus infection, Journal of Hepatology, vol.46, issue.1, pp.160-170, 2007.
DOI : 10.1016/j.jhep.2006.10.007

E. Santos, C. Yoshida, V. Rolla, J. Mendes, I. Vieira et al., Frequent occult hepatitis B virus infection in patients infected with human immunodeficiency virus type 1, Eur J Clin Microbiol Infect Dis, vol.22, pp.92-98, 2003.

N. Schnepf, P. Sellier, M. Bendenoun, J. Zini, M. Sanson-le-pors et al., Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy, Journal of Clinical Virology, vol.39, issue.1, pp.48-50, 2007.
DOI : 10.1016/j.jcv.2007.01.011

C. Stephan, A. Berger, A. Carlebach, T. Lutz, M. Bickel et al., Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus, Journal of Antimicrobial Chemotherapy, vol.56, issue.6, pp.1087-1093, 2005.
DOI : 10.1086/424012

C. Thio, Hepatitis B in the human immunodeficiency virusinfected patient: Epidemiology, natural history, and treatment, Semin Liver Dis, vol.23, pp.125-136, 2003.

C. Toro, V. Jimenez, C. Rodriguez, D. Romero, J. Rodes et al., Molecular and epidemiological characteristics of blood-borne virus infections among recent immigrants in Spain, Journal of Medical Virology, vol.75, issue.12, pp.1599-1608, 2006.
DOI : 10.1016/S0025-7753(01)71937-9